Expert Analysis

Clinical Update on First-Line Antiretroviral Therapy

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on First-Line Antiretroviral Therapy

Faculty:

Joel E. Gallant, MD, MPH
Charles B. Hicks, MD
Kathleen E. Squires, MD

CME CREDIT INFORMATION

Release Date: 03/27/08

Expiration Date: 03/26/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new findings regarding the effects of delaying or interrupting antiretroviral therapy
Describe new data from randomized studies comparing different boosted PIs and different NRTI backbones in first-line antiretroviral therapy
Cite new insights regarding cardiovascular risks associated with antiretroviral therapy
Recount new findings regarding the use of antiretroviral therapy in prevention of mother-to-child HIV transmission

Topics covered include:

The CASTLE Study: First-Line Atazanavir/Ritonavir Noninferior to Lopinavir/Ritonavir
Abacavir/Lamivudine in First-Line Regimens and Risk of Myocardial Infarction With Abacavir
Lopinavir/Ritonavir Tablet Once Daily vs Twice Daily
Impact of Sex and Race on First-Line Response
No Advantage to Initial Therapy With Double-Boosted PI Regimens
Outcomes of Initial Therapy in Clinical Trials vs Clinical Practice
Additional Data on Risks Associated With Treatment Interruption: SMART and Trivacan
Fixed-Duration Treatment of Acute and Early HIV Infection
Managing Pediatric Infection and Mother-to-Child Transmission

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.